# Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet

> **NCT00950404** · PHASE1 · COMPLETED · sponsor: **Pfizer's Upjohn has merged with Mylan to form Viatris Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Viagra 50 mg tablet
- **DRUG:** Formulation B ODT tablet 50 mg
- **DRUG:** Formulation C ODT tablet 50 mg
- **DRUG:** Formulation D ODT tablet 50 mg

## Key facts

- **NCT ID:** NCT00950404
- **Lead sponsor:** Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00950404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00950404, "Bioavailability of 3 Sildenafil Oral Disintegrating Tablet Formulations Compared to the Standard Oral Tablet". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00950404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*